Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables
Avantor (NYSE: AVTR) announced a collaboration with p-Chip Corporation on October 23, 2025 to co-develop "Smart Consumables" by embedding p-Chip microtransponder technology into Avantor's laboratory and clinical consumables.
The Smart Consumables (vials, slides, cassettes, tubes, plates) will carry a unique, secure identifier to enable end-to-end traceability, automated digital process control, and compliance with Chain-of-Identity (COI) requirements for life sciences, diagnostics, bio-manufacturing and healthcare workflows, addressing demands from individualized therapies such as cell and gene treatments.
Avantor (NYSE: AVTR) ha annunciato una collaborazione con p-Chip Corporation il 23 ottobre 2025 per co-sviluppare "Smart Consumables" inserendo la tecnologia microtransponder p-Chip all'interno dei consumabili di laboratorio e clinici di Avantor.
I Smart Consumables (ampolle, vetrini, cassette, tubi, piastre) porteranno un identificatore unico e sicuro per consentire la tracciabilità end-to-end, il controllo di processo digitale automatizzato e la conformità ai requisiti Chain-of-Identity (COI) per le scienze della vita, diagnostica, bio-manufacturing e flussi di lavoro sanitari, rispondendo alle esigenze di terapie personalizzate come i trattamenti cellulare e genici.
Avantor (NYSE: AVTR) anunció una colaboración con p-Chip Corporation el 23 de octubre de 2025 para co-desarrollar “Smart Consumables” mediante la incorporación de la tecnología de microtranspondedores de p-Chip en los consumibles de laboratorio y clínicos de Avantor.
Los Smart Consumables (viales, portaobjetos, cassettes, tubos, placas) llevarán un identificador único y seguro para habilitar la trazabilidad de punta a punta, control de procesos digitales automatizados y el cumplimiento de los requisitos Chain-of-Identity (COI) para flujos de trabajo de ciencias de la vida, diagnóstico, biofabricación y atención sanitaria, atendiendo a las demandas de terapias personalizadas como tratamientos celulares y génicos.
Avantor (NYSE: AVTR)는 2025년 10월 23일 p-Chip Corporation과 협력하여 Avantor의 연구실 및 임상 소모품에 p-Chip 마이크로트랜스폰더 기술을 탑재해 "Smart Consumables"를 공동 개발하기로 발표했습니다.
Smart Consumables(병, 슬라이드, 카세트, 튜브, 플레이트)는 고유하고 안전한 식별자를 통해 종단 간 추적성, 자동화된 디지털 프로세스 제어, 생명과학, 진단, 바이오제조, 보건 관리 워크플로우에 대한 Chain-of-Identity (COI) 요건 준수를 가능하게 하며, 세포 및 유전자 치료와 같은 개인화 치료의 수요를 충족합니다.
Avantor (NYSE: AVTR) a annoncé le 23 octobre 2025 une collaboration avec p-Chip Corporation pour co-développer les « Smart Consumables » en intégrant la technologie des micro-transpondeurs p-Chip dans les consommables de laboratoire et cliniques d'Avantor.
Les Smart Consumables (flacons, lamelles, cassètes, tubes, plaques) porteront un identifiant unique et sécurisé pour permettre une traçabilité de bout en bout, un contrôle de processus numérique automatisé et la conformité aux exigences Chain-of-Identity (COI) pour les sciences de la vie, le diagnostic, la biofabrication et les flux de travail en santé, répondant aux demandes des thérapies personnalisées telles que les traitements cellulaires et géniques.
Avantor (NYSE: AVTR) kündigte am 23. Oktober 2025 eine Zusammenarbeit mit p-Chip Corporation an, um gemeinsam „Smart Consumables“ zu entwickeln, indem die p-Chip-Mikrotransponder-Technologie in Avantors Labor- und Klinikausgaben integriert wird.
Die Smart Consumables (Fläschchen, Objektträger, Kästen, Röhrchen, Platten) tragen eine eindeutige, sichere Kennung, um eine End-to-End-Rückverfolgbarkeit, eine automatisierte digitale Prozesssteuerung und die Einhaltung der Chain-of-Identity (COI)-Anforderungen für Life-Science-, Diagnostik-, Bioherstellungs- und Gesundheitsarbeitsabläufe sicherzustellen und die Anforderungen personalisierter Therapien wie Zell- und Gentherapien zu adressieren.
Avantor (NYSE: AVTR) أعلنت عن تعاون مع p-Chip Corporation في 23 أكتوبر 2025 لتطوير مشترك لـ“Smart Consumables” من خلال إدراج تكنولوجيا مستشعرات p-Chip الدقيقة في consumables المختبرية والسريرية لشركة Avantor.
ستحتوي Smart Consumables (العبوات، الشرائح، الكاسات، الأنابيب، الأطباق) على معرف فريد وآمن لتمكين التتبع من الطرف إلى الطرف، والتحكم الرقمي الآلي في العمليات، والامتثال لمتطلبات Chain-of-Identity (COI) لعلوم الحياة والتشخيص والتصنيع الحيوي وتدفقات العمل الصحية، مع تلبية طلبات العلاجات المخصصة مثل العلاجات الخلوية والجينية.
Avantor (NYSE: AVTR)在2025年10月23日宣布与p-Chip Corporation开展合作，共同开发“Smart Consumables”，通过将p-Chip微型应答器技术嵌入Avantor的实验室和临床耗材中。
Smart Consumables（小瓶、载玻片、盒、试管、培养皿）将具有唯一且安全的标识符，以实现端到端可追溯性、自动化数字化过程控制，并符合生命科学、诊断、生物制造和医疗保健工作流程的Chain-of-Identity (COI)要求，满足个性化治疗（如细胞治疗和基因治疗）的需求。
- None.
- None.
Insights
Partnership creates a new product category that embeds digital IDs into consumables, supporting traceability for personalized therapies.
Embedding p-Chip microtransponders into consumables creates a defensible product differentiation for Avantor by converting passive labware into digitally addressable assets that can be read and verified throughout workflows.
The value depends on customer adoption, reader/infrastructure availability, and integration with existing lab information systems; commercial uptake will hinge on clear ROI for pharma and cell/gene therapy customers.
Watch for early pilot results with strategic customers, announcements of reader or software partnerships, and adoption milestones within
Digital identifiers in consumables directly target Chain‑of‑Identity and traceability needs in regulated workflows.
The technology can materially strengthen compliance by providing immutable, unique identifiers on vials, tubes, slides and plates, simplifying verification steps during manufacturing and clinical workflows.
Effectiveness depends on validation, data integrity, and secure linkage to electronic records; labs will require documented qualification protocols and evidence that embedding does not affect sample integrity.
Key near‑term items to monitor are validation studies, qualification packages for regulated environments, and any regulatory guidance or customer validation timelines expected in the next 6–18 months.
New product line will enable secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies
This partnership combines Avantor's industry leading expertise and scale with p-Chip's digital microtransponder technology platform. The collaboration will focus on engagement with joint strategic customers in life sciences, diagnostics, bio-manufacturing, and healthcare to provide solutions for digital process control that enable compliance with Chain-of-Identity ("COI") requirements.
The Smart Consumables developed under this collaboration will provide a next-generation solution with secure and trusted digital process control for COI compliance. Consumables, such as vials, slides, cassettes, tubes and plates will be embedded with a durable p-Chip microtransponder with a unique and secure identifier. This will enable end-to-end traceability and automated process control, ensuring that critical samples and reagents are tracked and verified at every step.
The growing demand for precision and individualized therapies is aggressively driving the need for high-fidelity sample traceability and a secure COI. This category of personalized therapeutics, including advanced cell and gene therapies, require patient samples to be securely and unambiguously identified, monitored and linked to all data throughout its end-to-end process, and to the therapeutic journey from collection to administration. By building digital identification directly into consumable labware, Smart Consumables help provide the level of tracking, authenticity verification, and compliance that these innovative treatments demand.
"This innovation supports Avantor's mission to enable scientific breakthroughs and allows us to meet high-value customer needs in rapidly evolving areas like personalized medicine," said Corey Walker, President of Laboratory Solutions at Avantor. "Embedding digital intelligence into our consumables will deliver a new level of traceability and process control for our customers and underscores our commitment to developing proprietary and digitally enabled lab solutions."
"Our microtransponder platform will play a pivotal role in advancing traceability and compliance in lab workflows through this collaboration," said Michael Hadjisavas, Chief Operating Officer, Life Sciences and Healthcare, p-Chip Corporation. "By equipping consumable labware with secure, unique digital identifiers, we are helping labs maintain an unbroken chain-of-identity for samples and reagents. We are confident that this not only streamlines quality control but also accelerates the digital transformation of pharmaceutical and healthcare processes – supporting better patient outcomes in the era of digital healthcare."
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
About p-Chip Corporation
p-Chip Corporation is a
Avantor Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com
Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com
p-Chip Media Contact
Lyda Guilfoyle
lyda@p-chip.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-partnership-with-p-chip-corporation-to-develop-solutions-for-digital-traceability-of-smart-consumables-302592029.html
SOURCE Avantor and Financial News
FAQ
What did Avantor (AVTR) announce on October 23, 2025 regarding smart consumables?
Which consumables will be embedded with p-Chip identifiers in the Avantor (AVTR) partnership?
How will Avantor's Smart Consumables support individualized therapies and cell and gene treatments?
Which industries will Avantor (AVTR) and p-Chip focus on for Smart Consumables commercial engagement?
What is the primary compliance benefit claimed for Avantor's Smart Consumables (AVTR)?
Does the Avantor (AVTR) release include financial guidance or commercialization timelines?
